Acrivon Therapeutics Inc (ACRV)

Dec 12, 2024, 3:25 PM EST - 2 months ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Oct 16, 2024, 4:00 PM EDT - 4 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 11, 2024, 8:00 AM EDT - 4 months ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Sep 18, 2024, 10:11 AM EDT - 5 months ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 14, 2024, 3:10 AM EDT - 5 months ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Jun 13, 2024, 2:00 PM EDT - 9 months ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

May 29, 2024, 8:00 AM EDT - 9 months ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 10 months ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 24, 2024, 7:16 PM EDT - 10 months ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 4:01 PM EDT - 10 months ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 16, 2024, 8:01 PM EDT - 11 months ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 10, 2024, 8:00 AM EDT - 11 months ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 9, 2024, 7:00 AM EDT - 11 months ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 3, 2024, 3:07 AM EDT - 11 months ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Mar 28, 2024, 8:00 AM EDT - 11 months ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 5, 2024, 4:30 PM EST - 1 year ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Feb 27, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 12, 2024, 4:00 PM EST - 1 year ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 21, 2023, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 9, 2023, 8:01 AM EST - 1 year ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 19, 2023, 4:32 PM EDT - 1 year ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 5, 2023, 4:05 PM EDT - 1 year ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 11, 2023, 7:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jun 22, 2023, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 2, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 25, 2023, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 26, 2023, 9:53 AM EDT - 2 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 6, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Nov 14, 2022, 10:16 PM EST - 2 years ago

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Nov 3, 2022, 7:52 AM EDT - 2 years ago

Acrivon Therapeutics sets IPO price range

Oct 19, 2022, 11:50 AM EDT - 2 years ago

Acrivon Therapeutics Begins U.S. IPO Rollout